Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation by Sanofi, as well
Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, with their key US
Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic
